Sanofi India Ltd

Sanofi India Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from a bearish to a mildly bearish trend. Despite a modest day gain of 1.84%, the stock remains under pressure amid broader sector challenges and a prolonged downtrend relative to the Sensex benchmark.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a marginal day change of -0.07%, the stock’s technical parameters and longer-term returns paint a challenging picture for investors in the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from bearish to mildly bearish trends. Despite a modest day gain of 1.79%, the pharmaceutical company’s longer-term technical outlook remains challenged, reflecting broader sector pressures and subdued market sentiment.

Sanofi India Ltd has seen its investment rating downgraded from Hold to Sell as of 15 June 2026, reflecting a combination of deteriorating technical indicators, subdued financial performance, and valuation concerns. Despite some strengths such as high return on equity and net-debt-free status, the company’s long-term growth outlook and recent market returns have raised caution among analysts.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a 4.11% gain on 16 Jun 2026, the stock’s broader technical outlook and fundamental scores suggest caution for investors amid persistent downward pressure and underperformance relative to the Sensex.

Sanofi India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 June 2026, providing investors with the most recent insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sanofi India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals and market performance.

Sanofi India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sanofi India Ltd has experienced a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting mixed signals from key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 0.37%, the stock continues to face headwinds amid broader sector challenges and a prolonged downtrend relative to the Sensex benchmark.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock faces persistent downward pressure, reflected in its price performance and technical metrics across weekly and monthly timeframes.

A sharp decline in Sanofi India Ltd shares has dragged the stock to a fresh 52-week low of Rs 3,057.6 on 29 Jun 2026, marking a significant 50.5% drop over the past year. This fall comes despite the company’s net-debt free status and a high return on equity, underscoring a complex interplay of valuation concerns and subdued growth prospects.

Sanofi India Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement in technical indicators and valuation metrics despite ongoing challenges in financial growth and market performance. The upgrade, effective from 25 May 2026, is driven primarily by a shift in technical trends, attractive valuation relative to peers, stable financial fundamentals, and a cautious but improving market sentiment.

Sanofi India Ltd has witnessed a subtle but notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 0.68%, the stock’s technical indicators present a complex picture, with weekly and monthly signals diverging and the company’s valuation remaining under pressure compared to broader market benchmarks.

A sustained decline has pushed Sanofi India Ltd to within 1.44% of its 52-week low of Rs 3,151.05 as of 25 Jun 2026, marking a near half-year low point for the pharmaceutical company amid a backdrop of underwhelming financial performance and persistent market headwinds.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sanofi India Ltd has seen its investment rating downgraded from Hold to Sell as of 11 May 2026, reflecting a combination of deteriorating technical indicators, flat financial performance, and persistent underperformance against benchmarks. Despite some strengths in management efficiency and valuation, the overall outlook has weakened, prompting a reassessment of the stock’s attractiveness.